Overall, this suggests that BCL2L1, BIRC2, and ACTN4 are potentially major regulators of TRAIL-induced caspase-3/7 in breast cancer and that their LOF has the potential to overcome resistance to TRAIL-induced cytotoxicity. The gene discussed is ACTN4; the disease is breast carcinoma.